Clinical trials
for patients

We are conducting this study to evaluate how well enfortumab vedotin works when given as monotherapy or with pembrolizumab to patients with urothelial cancer. We also want to find out the side effects of giving enfortumab vedotin as monotherapy or with pembrolizumab for urothelial cancer.

The objective of the study is to evaluate the efficacy and safety of two doses of SAR441344 administered by different routes in participants with relapsing multiple sclerosis (RMS).

This study will be divided into two phases. The main objective of the first phase of this trial is to analyze the safety of PM14, a new experimental drug, at different doses. Also to determine the effect (if any) of PM14 on their disease and the possible adverse effects (if any) that may develop. The study, initially, will be conducted in a small group of patients who will be administered a given dose of PM14. If these patients tolerate the dose well (i.e., if they have few or easily treatable a...

The purpose of the study is to test two different dosing schedules of venetoclax . 800 mg venetoclax in combination with polatuzumab vedotin and R-CHP for 5 days and 800 mg venetoclax in combination with polatuzumab vedotin and R-CHP for 10 days . to determine if the combination of the study drugs (also called the study treatment) is tolerated and to understand how your body processes the study treatment. The dose and dosing schedule of polatuzumab vedotin and R-CHP will always be the same.

The aim of this study is to test the safety and tolerability of monotherapy and combination therapy, to find out what effects, if any, these therapies have on people and their cancer and to select the safe and tolerable dose of INCB106385 to be studied further as monotherapy or combination therapy.

The main goal of this trial is to test the safety of the MCLA-128 trial drug in patients with solid (epithelial-type) tumors like yours and to see what effects it has on patients and their cancer.

The main objective of this study is to find out how well Debio 1143 works and how safe it is compared to a placebo. A placebo is an inactive substance that looks like the study drug, but does not contain any active drug. Researchers use a placebo to see if the study drug works better or if it is as safe as taking nothing.

The aim of the trial is to get your own white blood cells to attack all those cells that express a protein called CD19 that is present on tumor cells. These modifications will be made in the laboratory and will alter the genes of your T lymphocytes. Once the cells, which we will call ARI-0001, have been modified, they will be infused into your vein. The purpose of this study is to determine if these ARI-0001 cells are safe and effective in eradicating the disease.